Blueprint set out to change that, representing the seller, a private family office, in the fully marketed disposition of the facility following a multi-year acquisition, stabilization, and repositioning strategy. The result is a state-of-the-art proton therapy and oncology center anchored by Tennessee Oncology under a long-term triple-net lease covering both the real estate and radiation equipment — with a guarantee from OneOncology, a national oncology platform recently valued at $7.4 billion in its acquisition by Cencora.

Blueprint’s national marketing process attracted strong interest from healthcare REITs, private equity groups, institutional investment managers, and regional health systems. The asset’s location within the Nashville MSA — one of the nation’s premier healthcare markets — added further depth to the buyer pool. The property was ultimately acquired by a healthcare real estate investment group that had been evaluating the proton therapy sector but had not previously identified an opportunity that met its criteria.

The result is a new market precedent and proof that highly specialized healthcare facilities, when properly positioned, can trade at institutional pricing through a competitive process.